secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001104659-26-021904
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting
--------------------------------------------------------------------------------

- Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.
- Phase 2 SHIMMER data showed 86% slowing of decline on NPI-12 vs placebo; no motor function worsening.
- No approved medications for DLB psychosis; traditional antipsychotics are contraindicated.
- Next study will use validated endpoints for neuropsychiatric symptoms; patients randomized to 100 mg zervimesine or placebo.
- Company expects to meet with FDA Division of Psychiatry by midyear 2026 to discuss the program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926021904/0001104659-26-021904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926021904/tm267638d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-021904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer